Good Intentions, Bad Stock

Though long admired for its roster of disease-fighting drugs, Vertex Pharmaceuticals offers few catalysts to jump start a falling stock price.

Once a potent biotech name applauded for its cutting-edge drugs, Vertex Pharmaceuticals has lost its mojo.

Sales of its blockbuster hepatitis C drug, Incivek, are falling. And on Thursday, the company's third-quarter financial results disappointed investors with revenue falling 49% to $336 million and a lackluster earnings per share of 13 cents....